Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- overall survival
研究概览
简要总结
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies.
Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored.
Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers.
Method: Retrospective and prospective monocentric cohort study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma
- •Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment
- •Age ≥ 18 years old
- •Diagnosed from 2015 onwards
- •Signed Consent
- •Affiliation to a social security scheme (including CMU (Universal health coverage))
排除标准
- •Patient under guardianship, curatorship or safeguarding of justice
- •Pregnant or breastfeeding woman
- •Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.
- •Refusal to participate in the study
- •Patient on AME (state medical assistance)
- •Persons deprived of liberty by a judicial or administrative decision
- •Persons under psychiatric care
结局指标
主要结局
overall survival
时间窗: observation from first cancer treatment date until date of death or 10 years follow up if patient alive
Overall survival (OS): vital status (alive/deceased)
次要结局
未报告次要终点